Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

Summary

This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial ovarian cancer who cannot achieve R0 surgery as assessed by imaging (Suidan's CT score) or laparoscopy (Fagotti score), or cannot tolerate surgery.

Timeline

Start

2024-06-18

Primary completion

2026-05-31

Completion

2026-05-31

Drugs

Indications